ELISA TSO BOMGAARS, M.D.

CURRICULUM VITAE

Ironwood Cancer & Research Centers a division of

Ironwood Physicians, PC

PROFESSIONAL ADDRESS

5810 W Beverly Lane
Glendale, AZ 85306
Phone: 623-312-3000
Fax: 623-312-3060

JOB POSITIONS

10/21/2013 – present	IRONWOOD PHYSICIANS, PC Phoenix, Arizona 85027
07/01/2007- 10/18/2013	ONCOLOGY ASSOCIATES, PC Omaha, Nebraska 68114 Staff Physician
07/01/2004-06/30/2007	HEARTLAND ONCOLOGY& HEMATOLOGY, LLP Council Bluffs, Iowa 51503 Staff Physician

EDUCATION

07/01/2001-06/30/2004	CLEVELAND CLINIC FOUNDATION Cleveland, Ohio 44195 Hematology-Oncology Fellowship
07/01/1998-06/30/2001	CLEVELAND CLINIC FOUNDATION Cleveland, Ohio 44195 Internal Medicine Residency
6/11/1990-04/30/1997	UNIVERSITY OF THE PHILIPPINES, COLLEGE OF MEDICINE Manila, Philippines

Graduate of the Seven-Year Integrated Arts and Medicine Program,
Which accepts only 40 out of 20,000 applicants annually and which
conferred the following degrees:

Bachelor of Science in Basic Medical Sciences, Cum Laude
awarded after the first 4 years of basic science

Doctor of Medicine, Cum Laude (Class rank: 4th)
received after last 3 years of clinical sciences, clerkship and

Rotating Internship at the Philippine General Hospital,
Taft Avenue, Manila

RESEARCH EXPERIENCE

ONCOLOGY ASSOCIATES, PC
METHODIST ESTABROOK CANCER CENTER
Omaha, Nebraska 68114

Roche Protocol NP 25163: A Phase I, Randomized, Open-Label, Multi-Center, Multiple Dose Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO5185426 Administered as 240 mg Tablets to Previously Treated BRAF V600E Positive Metastatic Melanoma Patients (BRIM4)

- Investigator 2010

Pfizer A4021018-1023: Phase 3 Trial of Erlotinib Alone or in Combination with CP-751,871 in Patients with Advanced NSCLC of Non-Adenocarcinoma Histology

- Investigator 2009

Subinvestigator to multiple CALGB, SWOG, ECOG and NSABP studies.

HEARTLAND ONCOLOGY & HEMATOLOGY, LLP
Council Bluffs, Iowa 51503

ARCCS: Open Label, Non-Comparative Treatment Protocol for the use of Sorafenib in Patients with Advanced Renal Cell Carcinoma (Protocol #11868)

- Investigator 2005

Pfizer A6181037: A SU011248 Expanded Access Protocol For Patients with Cytokine-Refractory or Cytokine-Intolerant Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols but May Derive Benefit From Treatment with SU011248

- Investigator 2006

T. Singh, E. Tso et al. Axillary lymph node metastasis from papilloma of the breast. ASCO 2006, Abstract 10764.

Subinvestigator to multiple CALGB, SWOG, ECOG and NSABP studies.
CLEVELAND CLINIC FOUNDATION
Cleveland, Ohio 44195

E Tso, R Baz, K Marchant, et al. Aspirin prophylaxis during treatment of multiple myeloma using liposomal doxorubicin, vincristine, decreased-frequency dexamethasone & thalidomide decreases post-treatment thrombosis. Poster presentation at the 2003 American Society of Clinical Oncology Annual Meeting.

E Tso, D Adelstein et al. Is the second primary malignancy an important competing cause of death in patients with squamous cell head and neck cancer? Poster presentation at the 2004 American Society of Oncology Annual Meeting.

M Markman, E Tso, et al. The real-life variability of CA 125 in ovarian cancer patients. Poster presentation at the 2004 American Society of Oncology Annual Meeting.

B Yoder, E Tso, M Skacel, et al. The Expression of Fascin, an Actin-Bundling Motility Protein, Correlates with Hormone Receptor–Negative Breast Cancer and a More Aggressive Clinical Course. Poster presentation at the 2004 San Antonio Breast Cancer Symposium. Published in Clin Cancer Res 2005 11: 186-192.

GT Budd, E Tso, et al. Using novel protein antibodies on tissue microarrays (TMAs) for breast cancer prognostication. Poster presentation at the 2004 American Society of Oncology Annual Meeting.

E Tso, R Schilz, et al. Demonstrated the usefulness of epoprostenol therapy for pulmonary hypertension in sarcoidosis. Podium presentation at the American College of Chest Physicians 2000 Annual Meeting.

E Tso, G Hoffman, et al. Assessed the utility of magnetic resonance imaging in diagnosis and treatment of Takayasu's arteritis. Podium presentation at the American College of Rheumatology 63rd Annual Scientific Meeting and won Honorable Mention for poster presentation at the 1999 Ohio American College of Physicians Meeting. Published in Arthritis and Rheumatism Vol. 46, No. 6, June,2002, pp 1634-1642.

E Hsi, S Sup, C Alemany, E Tso, et al. MAL is expressed in a subset of Hodgkin lymphomas and identifies a population of patients with poor prognosis. Poster presentation at the 2004 American Society of Hematology Annual Meeting. Published in Am J Clin Pathol. 2006; 125(5): 776-782.

B Yang, BJ Yoder, AA Roma, L Wang, S Tarr, S Laniauskas, E Tso, T Choueiri, GT Budd, JP Crowe, DG Hicks. The loss of 14-3-3 sigma (σ) protein expression in invasive adenocarcinoma of the breast is associated with promoter

hypermethylation and a more favorable clinical outcome. Poster presentation at the 2005 San Antonio Breast Cancer Symposium.

GT Budd, BJ Yoder, SM Tarr, E Tso, et al. Comparison of ER and PR determination by pathologists vs an image analysis system. Poster presentation at the 2004 San Antonio Breast Cancer Symposium.

DG Hicks, SM Tarr, T Ruddy, M Skacel, E Downs-Kelly, BJ Yoder, E Tso, et al. Expression of a cytoskeletal focal adhesion protein paxillin, in breast cancer; an immunohistochemistry (IHC) and image analysis study. Poster presentation at the 2004 San Antonio Breast Cancer Symposium

T Choueiri , BJ Yoder, E Tso, et al. Comparison of rabbit and murine monoclonal antibodies for immunohistochemical analysis of ER and PR. Poster presentation at the 2004 San Antonio Breast Cancer Symposium.

M Hussein, P Elson, E Tso, et al. Evaluated the effectiveness and tolerability of combined doxil, vincristine, decadron and thalidomide in relapsed/ refractory multiple myeloma. Poster presentation at the 2002 American Society of Hematology Annual Meeting.

PHILIPPINE GENERAL HOSPITAL
Manila, Philippines

05/05/1997-06/05/1998 A Balgos, E Tso, et al. Evaluated the use of flutter device Vs incentive spirometer in the reduction of perioperative complications of upper abdominal surgery.

1993-1994 E Tso, J Castaneda, et al, Pharmacology 201 Research, University of the Philippines. Compared the antipyretic effects of orally administered Tanglad (Andropogon citratus) leaf decoction and paracetamol on Brewer's yeast-induced pyrexia among male Sprague-Dawley rats.

1992-1993 E Tso, B Bautista, et al, Physiology 201 Research, University of the Philippines. Examined the effects of rice grain dust on the pulmonary function of male rice mill workers.

1992-1993 E Tso, E Balanag, et al, Biochemistry 203 Research, University of the Philippines. Elucidated the effects of vehicular emissions on bronchial lavage levels of alkaline phosphatase, lactate dehydrogenase, total proteins, and white blood cell counts in Rattus rattus.

HONORS AND AWARDS

1999 HONORABLE MENTION, POSTER PRESENTATION AT 1999 OHIO AMERICAN COLLEGE OF PHYSICIAN MEETING

1997	Overall 4th Place in the Philippine Physician Licensing Examination
1997	Outstanding Intern in Internal Medicine Outstanding Intern in Pediatrics Outstanding Intern in Psychiatry Outstanding Intern in Rehabilitation Medicine Outstanding Intern in Surgery
1997	Phi Kappa Phi Award for Overall Academic Excellence and Phi Sigma Award for Excellence in the Biological Sciences
1996-1997	College Scholar, University of the Philippines
1990-1992	University Scholar, University of the Philippines

EXTRACURRICULAR ACTIVITIES

2004-2006	Participated in free cancer screening clinics at Jennie Edmundson Hospital
1999	Negotiated the acquisition of 2 portable ventilators for the expansion of the Philippine General Hospital home ventilatory care program.
1997	Pahinungod. Coordinated medical and surgical missions throughout the Philippines, drafted the ER volunteers program operations module.
1994-1995	LIKAS. Procured funds for the medications of charity patients through garage sales and organized community medical missions.
1992-1994	Medical Students' Society. Engaged in fundraising activities to improve hospital facilities.

LANGUAGE SKILLS AND INTERESTS

Fluent in Filipino, Mandarin, Fukien, Cantonese and English.
Learning Spanish.

RESEARCH PROTOCOLS: SUB-INVESTIGATOR RESPONSIBILITIES

Amgen Protocol 20060136: A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer. (2007-)

Astra Zeneca Protocol D4200C00036: A Phase III, Randomized, Double-Blinded, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) versus Pemetrexed alone in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-Cancer Therapy. (2007 – 2008)

Amgen Protocol 20060362: An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 with Exemestane or Fulvestrant in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer (2008 -)

Pfizer Protocol A6181104: A Randomized, Phase 2B Study of Sunitinib Plus Oxaliplatin, 5-Fluorouracil and Leucovorin (FOLFOX) Versus Bevacizumab Plus FOLFOX as First-Line Treatment In Patients with Metastatic Colorectal Cancer (2008 -)

Sanofi-Aventis Protocol: A Multicenter, Randomized, Double-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-Line Treatment of Patients with Metastatic Colorectal Cancer Treated with Oxaliplatin/5-FU/LV (2007 – 2008)

Novacea Protocol 011-007: A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2) (2007)

Abbott Protocol M10-301: A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in

Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment (2009-)

Genentech Protocol TDM4370g/Roche Protocol BO21977: A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs Capecitabine + Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy (EMILIA) (2009-)

Novartis Protocol CRAD001Y2301: A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole (BOLERO 2). (2009-)

Novartis Protocol CRAD001J2301: A Randomize Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First Line Therapy in Women with HER2 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO 1). (2009-)

Imclone Protocol CP12-0606/TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of iMC-1121 B Plus Docetaxel versus Placebo Plus Docetaxel in Previously Untreated Patients with HER2-negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer. Protocol IMCL CP12-0606/TRIO-012. (2010 –

Novartis Protocol CRADN2301 : A Randomized Double-Blind, Placebo-Controlled, Multicenter phase III Study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapy (PILLAR 2) (2010 –

GlaxoSmith Kline Protocol LPT112515: A Randomized, Phase III, Open-Label, Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-line Trastuzumab plus Chemotherapy in Subjects with HER2-positive Metastatic Breast Cancer (HALT-MBC) (2010 –

Peregrine Protocol PPHM 1001: A Randomized, Open-Label, Phase 2 Trial of Paclitaxel/Carboplatin With or Without Bavituximab in Patients with Previously Untreated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer. (2010 –

Peregrine Protocol PPHM 0902: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer. (2010 -

Novocure Protocol EF-24/Lunar: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure (LUNAR) (2018-).
BeyondSpring Pharmaceuticals Inc. Protocol 450-0001/Dublin-3: Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion (DUBLIN-3) (2017-).
G1 Therapeutics Protocol G1T28-05: Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer (2017-)
Pharma Mar Protocol PM1183-C-003-14: Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial) (2016-)

Eli Lilly and Company Protocol LUN 288/I6A-MC-CBBE: A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung (2016-2018)

Hoffmann-La Roche Protocol GO29436: A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (2015-)

AstraZeneca Protocol D4191C00004: A Phase III, Open Label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum Based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC) (2014-2018)

AstraZeneca Protocol D4191C00001: A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC) (2014-2017)

Peregrine Protocol PPHM1202: SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer (2014-2017)

Breast Cancer Trials

Boehringer Ingelheim BI1280-0022: Xenera-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to

compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2-metastatic breast cancer and non-visceral disease (2019-)

Daiichi Sankyo Protocol DS8201-A-U303: A Phase-3, multicenter randomized, open-label, active-controlled trial of DS-8201A, an anti-her2-antibody drug conjugate (ADC) versus treatment of physician's choice for HER2low, unresectable and/or metastatic breast cancer subjects.(2019 -)

Daiichi Sankyo Protocol DS8201-A-U301: A Phase 3, multicenter, randomized, open-label, active-controlled of DS-8201A, an anti-HER2-antibody drug conjugate, versus treatment of investigator's choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1(2019-)

Novartis Pharmaceuticals Protocol CLAG525B2101: A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or second line therapy in patients with advanced triple-negative breast cancer (2018-)

Odonate Therapeutics Protocol ODO-TE-V301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane

Merrimack Pharmaceuticals Protocol MM-121-02-02-10/ Sherboc: Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC) (2018-)

Macrogenics, Inc. Protocol CP-MGAH22-04: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With

HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment (2016-)
Celgene Corporation Protocol CC-486-BRSTM-001: A Phase 2, Randomized, Open-label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women With ER+, HER2- Metastatic Breast Cancer Who Have Progressed on an Aromatase Inhibitor (2015-2017)
Novartis Pharmaceuticals Protocol CLEE011A2404: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease COMPLEEMENT-1 (2017-)
Novartis Pharmaceuticals Protocol CLEE011XUS29: A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor (2017-)
Novartis Pharmaceuticals Protocol CLEE011XUS29: A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor (2017-)
Merck Sharp & Dohme Corp. Protocol MK3475-119: A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119) (2016-2017)
Novartis Protocol CBYL719C2301A: Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With

Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment (2016-)
Novartis Protocol CLEE011F2301:A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment (2015-)
Eli Lilly Protocol I3Y-MC-JPBM: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting (2015-)
Novartis Protocol CLEE011A2301:A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease (2014-)
Pfizer protocol A5481023: Multicenter, Randomized, Double-Blind, Placebo-Controlled,Phase 3 Trial Of Fulvestrant (Faslodex (Registered)). With Or Without PD-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy (2013-)
Puma Biotechnology Protocol PUMA-NER-1301: A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA) (2013-)
Celgene Corporation Protocol ABI-007-MBC-001: A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-

Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer (2013-2017)
F. Hoffmann-La Roche Ltd / Genentech Inc Protocol MO27775: A Randomized, Two-arm, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-positive and Hormone Receptor-positive Advanced (Metastatic or Locally Advanced) Breast Cancer (2012-)

Pancreatic Cancer Trials

Incyte Corporation INCB 18424-362: A Randomized, Double-Blind, Phase 3 Study of the Janus Kinase (JAK) 1/2 Inhibitor, Ruxolitinib, or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study) (2014-2017)
Gilead Sciences Protocol GS-US-370-1296: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase (2014-2017)
Ovarian Cancer Trials

Tesaro, INC. Protocol PR-30-5020-C: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (2016-2018)
Prostate Cancer Trials

Roche Ltd Protocol CO39303 IPATential150: Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150) (2017-)

Bayer Healthcare Pharmaceuticals Protocol BAY 1841788 / 17777: A randomized, double–blind, placebo–controlled Phase III study of ODM–201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone–sensitive prostate cancer

Janssen Research & Development, LLC on behalf of Aragon Pharmaceuticals, Inc. Protocol 56021927PCR3003: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy (ATLAS) (2016-)

Sotio a.s. SP005: A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy (2014-)

Colorectal Cancer Trials

AbbVie Protocol M14-064: Phase 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab.(2018-)

Lymphoma Trials

Bayer Healthcare Pharmaceuticals Inc., Protocol BAY 80-6946 / 17833: A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL) - CHRONOS-4 (2018-)

TG Therapeutics, Inc Protocol UTX-TGR-205: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (2016-)

Novartis Protocol OFB114612: A Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) Which Has Relapsed after Rituximab Therapy (2011-2017)

Novartis Protocol CRAD001N2301: A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy (2010-2016)

Myeloma Trials

Merck Sharp & Dohme MK-3475-183-01: A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183) (2016-)

Millennium Pharmaceuticals Protocol C16014: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral IXAZOMIB (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma (2013-)

CLL Trials

TG Therapeutics Protocol UTX-TGR-304: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) (2016-)

TG Therapeutics Protocol UTX-IB-301: Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) (2015-)
Genentech Protocol ML29538: A Phase II, Open-Label Study Of Obinutuzumab Plus Bendamustine (BG) In Patients With Previously Untreated Chronic Lymphocytic Leukemia (2015-)
Melanoma Cancer Trials

Merck Sharp & Dohme Corp. Protocol 7902-004: A Multicenter, Open-label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) in Participants with Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent (LEAP-004)
Polynoma LLC Protocol 103A-301: A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence (2015-)
Head & Neck Cancer Trials

Merck Sharp & Dohme Protocl MK-3475-040-10: A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer (2016-)
Urothelial Carcinoma Trials

Merck Sharp & Dohme Corp. Protocol MK3475-361: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma (2016-)
Renal Cell Carcinoma Trials

Bristol-Myers Squibb Protocol CA 209-920: Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate

920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) (2017-)
Registry trials

Guardant Health Protocol 01-MX-003: GEODE: Registry of Guardant360® Use and Outcomes In People With Advanced Cancer